N-Acetylcysteine is useful as a mucolytic agent for treatment of chronic bronchitis and other pulmonary diseases complicated by the production of viscous mucus. It is also used as an antidote to paracetamol (acetaminophen) poisoning and found to be effective for the prevention of cardiotoxicity by doxorubicin and haemorrhagic cystitis from oxazaphosphorines. After an oral dose of N-acetylcysteine 200 to 400 mg the peak plasma concentration of 0.35 to 4 mg/L is achieved within 1 to 2 hours. Although the data are conflicting, it appears that the administration of charcoal may interfere with drug absorption, with up to 96% of the drug adsorbed on to the charcoal. Information on absorption in the presence of food or other drugs is not available. The volume of distribution ranges from 0.33 to 0.47 L/kg and protein binding is significant, reaching approximately 50% 4 hours after the dose. Pharmacokinetic information is not available as to whether or not N-acetylcysteine crosses the blood-brain barrier or placenta, or into breast milk. Renal clearance has been reported as 0.190 to 0.211 L/h/kg and approximately 70% of the total body clearance is nonrenal. Following oral administration, reduced N-acetylcysteine has a terminal half-life of 6.25h. Little is known of the metabolism of this agent, although it is believed to be rapidly metabolised and incorporated on to proteins. The major excretory product is inorganic sulphate. Frequently reported side effects are nausea, vomiting and diarrhoea. Biochemical and haematological adverse effects are observed but are not clinically relevant. Drug interactions of clinical significance have been observed with paracetamol, glutathione and anticancer agents.
J Chromatogr. 1986 Oct 31;382:99-106
[PMID:
3782418]
J Chromatogr. 1984 Nov 9;311(1):170-5
[PMID:
6520160]
Eur J Respir Dis. 1983 Aug;64(6):405-15
[PMID:
6350033]
Arzneimittelforschung. 1989 Mar;39(3):382-6
[PMID:
2757663]
J Chromatogr. 1986 Feb 21;352:27-33
[PMID:
3700509]
Semin Oncol. 1983 Mar;10(1 Suppl 1):2-6
[PMID:
6836323]
J Chromatogr. 1987 Jan 9;385:343-56
[PMID:
3558591]
Eur J Respir Dis Suppl. 1980;111:93-108
[PMID:
7011836]
Eur J Respir Dis. 1987 Feb;70(2):73-7
[PMID:
3817074]
Semin Oncol. 1983 Mar;10(1 Suppl 1):56-61
[PMID:
6836327]
Annu Rev Pharmacol Toxicol. 1983;23 :87-101
[PMID:
6347057]
Respiration. 1986;50 Suppl 1:31-42
[PMID:
3809741]
Am J Hosp Pharm. 1981 Jul;38(7):1022-4
[PMID:
7258201]
J Chromatogr. 1986 Jan 24;374(2):251-7
[PMID:
3958085]
Biochem J. 1933;27(5):1716-8
[PMID:
16745290]
J Chromatogr. 1984 Aug 10;309(2):261-7
[PMID:
6480777]
Eur J Clin Pharmacol. 1988;34(1):77-82
[PMID:
3360052]
Clin Pharmacokinet. 1978 May-Jun;3(3):247-54
[PMID:
657688]
Eur J Clin Pharmacol. 1986;31(2):217-22
[PMID:
3803419]
J Chromatogr. 1985 Jun 26;327:261-7
[PMID:
4030959]
Semin Oncol. 1983 Mar;10(1 Suppl 1):49-52
[PMID:
6132449]
Yakugaku Zasshi. 1981 Nov;101(11):1002-9
[PMID:
7343655]
Respiration. 1986;50 Suppl 1:26-30
[PMID:
3809740]
J Pharm Sci. 1982 Dec;71(12):1384-6
[PMID:
7153888]
J Chromatogr. 1983 Dec 30;282:495-500
[PMID:
6671013]
Eur J Cancer Clin Oncol. 1982 Jan;18(1):113-4
[PMID:
7200891]
Eur J Respir Dis Suppl. 1980;111:52-8
[PMID:
6938411]
Biochem Pharmacol. 1966 Oct;15(10):1523-35
[PMID:
5971807]
J Pharm Sci. 1984 Jul;73(7):996-8
[PMID:
6470970]
Cancer Treat Rep. 1976 Apr;60(4):437-43
[PMID:
1277219]
Biopharm Drug Dispos. 1987 Jul-Aug;8(4):365-75
[PMID:
3620595]
Clin Toxicol. 1981 Mar;18(3):283-90
[PMID:
7237961]
Semin Oncol. 1983 Mar;10 (1 Suppl 1):76-85
[PMID:
6340205]
Clin Chim Acta. 1979 Jul 16;95(2):189-200
[PMID:
527218]
Eur J Respir Dis Suppl. 1980;111:45-51
[PMID:
6938410]
